These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21093488)

  • 1. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.
    Nicholson CO; Costin JM; Rowe DK; Lin L; Jenwitheesuk E; Samudrala R; Isern S; Michael SF
    Antiviral Res; 2011 Jan; 89(1):71-4. PubMed ID: 21093488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
    Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
    Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan.
    Piccini LE; Carro AC; Quintana VM; Damonte EB
    Virus Res; 2020 Dec; 290():198150. PubMed ID: 32866533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.
    Chan CYY; Low JZH; Gan ES; Ong EZ; Zhang SL; Tan HC; Chai X; Ghosh S; Ooi EE; Chan KR
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31533998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
    Ayala-Nuñez NV; Jarupathirun P; Kaptein SJ; Neyts J; Smit JM
    Antiviral Res; 2013 Oct; 100(1):238-45. PubMed ID: 23994499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.
    Chotiwan N; Roehrig JT; Schlesinger JJ; Blair CD; Huang CY
    Virology; 2014 May; 456-457():238-46. PubMed ID: 24889243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells.
    Chareonsirisuthigul T; Kalayanarooj S; Ubol S
    J Gen Virol; 2007 Feb; 88(Pt 2):365-375. PubMed ID: 17251552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate-related inhibitors of dengue virus entry.
    Hidari KI; Abe T; Suzuki T
    Viruses; 2013 Feb; 5(2):605-18. PubMed ID: 23389466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro analysis of synthetic peptides in blocking the entry of dengue virus.
    John AM; Jittmittraphap A; Chattanadee S; Alwin Prem Anand A; Shenbagarathai R; Leaungwutiwong P
    Virus Res; 2019 Jan; 260():142-150. PubMed ID: 30508603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro.
    De Burghgraeve T; Kaptein SJ; Ayala-Nunez NV; Mondotte JA; Pastorino B; Printsevskaya SS; de Lamballerie X; Jacobs M; Preobrazhenskaya M; Gamarnik AV; Smit JM; Neyts J
    PLoS One; 2012; 7(5):e37244. PubMed ID: 22624001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA.
    Moi ML; Lim CK; Kotaki A; Takasaki T; Kurane I
    J Virol Methods; 2010 Feb; 163(2):205-9. PubMed ID: 19781573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses.
    Flipse J; Diosa-Toro MA; Hoornweg TE; van de Pol DP; Urcuqui-Inchima S; Smit JM
    Sci Rep; 2016 Jul; 6():29201. PubMed ID: 27380892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains.
    Puerta-Guardo H; Mosso C; Medina F; Liprandi F; Ludert JE; del Angel RM
    J Gen Virol; 2010 Feb; 91(Pt 2):394-403. PubMed ID: 19828759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies.
    Carro AC; Piccini LE; Damonte EB
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006685. PubMed ID: 30092029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection.
    Narayan R; Tripathi S
    Front Cell Infect Microbiol; 2020; 10():580096. PubMed ID: 33123500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.